This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Roche’s alleged exclusion of biosimilars sent to Belgian authority’s board

By Nicholas Hirst ( December 2, 2025, 17:29 GMT | Insight) -- Roche Group has seen Belgian antitrust enforcers escalate a probe into allegations it hindered competition from biosimilar challengers to its own cancer treatments, according to a senior official. Anne-Charlotte Prévot, a prosecutor at the Belgian Competition Authority, said investigators had sent a draft decision with concerns to the watchdog's board. Roche Group has seen Belgian antitrust enforcers escalate a probe into allegations it hindered competition from biosimilar challengers to its own cancer treatments, a senior official said Tuesday....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections